Householder Group Estate & Retirement Specialist LLC Sells 1,351 Shares of Amgen Inc. (NASDAQ:AMGN)

Householder Group Estate & Retirement Specialist LLC lowered its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 46.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,584 shares of the medical research company's stock after selling 1,351 shares during the quarter. Householder Group Estate & Retirement Specialist LLC's holdings in Amgen were worth $412,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new position in Amgen in the 3rd quarter valued at approximately $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen during the 3rd quarter worth $29,000. Hershey Financial Advisers LLC acquired a new stake in Amgen in the second quarter valued at approximately $30,000. Matrix Trust Co purchased a new stake in shares of Amgen in the 3rd quarter valued at approximately $36,000. Finally, Livelsberger Financial Advisory purchased a new stake in Amgen during the third quarter worth approximately $56,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of Amgen stock traded up $2.68 on Friday, reaching $272.11. 3,244,015 shares of the company traded hands, compared to its average volume of 3,140,853. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The company has a 50 day moving average of $273.95 and a 200 day moving average of $307.22. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The firm has a market capitalization of $146.27 billion, a PE ratio of 34.84, a PEG ratio of 2.68 and a beta of 0.56.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company's revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the prior year, the firm posted $4.96 earnings per share. Equities analysts forecast that Amgen Inc. will post 19.57 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This is a positive change from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.50%. Amgen's dividend payout ratio is 115.24%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on AMGN. Piper Sandler decreased their price target on Amgen from $344.00 to $310.00 and set an "overweight" rating for the company in a report on Thursday, January 2nd. StockNews.com downgraded Amgen from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Wells Fargo & Company reduced their target price on Amgen from $335.00 to $280.00 and set an "equal weight" rating on the stock in a research report on Friday, January 10th. Jefferies Financial Group restated a "buy" rating and issued a $380.00 price objective on shares of Amgen in a report on Tuesday, November 12th. Finally, Truist Financial reduced their price objective on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research note on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Amgen has an average rating of "Hold" and an average price target of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.